SCHEMBL1947874

SCHEMBL1947874

COCCNc1nn2cc(-c3ccccc3)nc2s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 6/20 0.57
SMN1; SMN2 Q16637 5/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
KDM4E B2RXH2 2/20 0.55
HSD17B10 Q99714 1/20 0.55
TP53 P04637 7/20 0.54
ALOX15 P16050 2/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
PKM P14618 1/20 0.54
RECQL P46063 1/20 0.54
MAPT P10636 5/20 0.51
HPGD P15428 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946947 0.89 F2RL3 (0.60) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1947772 0.89 MAPT (0.52) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1947329 0.89 F2RL3 (0.44) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1944797 0.88 F2RL3 (0.44) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1944826 0.87 MAPT (0.47) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1944460 0.87 TP53 (0.51) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1944433 0.87 F2RL3 (0.62) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1943679 0.87 F2RL3 (0.62) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL1947813 0.86 F2RL3 (0.63) F2RL3SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL15603263 0.85 FYN (0.46) F2RL3SMN1; SMN2RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R F2RL3 1121/4885SMN1; SMN2 4370/4885RAB9A 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.